HR Execs on the Move

Pharmaceutical Product Development

www.ppdi.com

 
The Pharmaceutical Product Development, LLC is a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.ppdi.com
  • 929, North Front Street
    Wilmington, NC USA 28401
  • Phone: 910.251.0081

Executives

Name Title Contact Details
Martina KOVAC
VP, Global Product Development-Vaccines | Clinical Research at PPD, part of Thermo Fisher Scientific Profile
Jai Balkissoon
Vice President, Immuno-Oncology,Global Product Development Profile
Sudhakar Sridharan
Executive Medical Director, Global Product Development, Rheumatology & Immunology Profile
Louis Griffel
Executive Medical Director - Global Product Development Profile
Binh Nguyen
VP Global Product Development Profile

Similar Companies

CG Pharmaceuitcals

CG Pharmaceuitcals is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verona Pharma

Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.

Kamiya Biomedical Company

Kamiya Biomedical Company is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicuRx Pharmaceuticals

MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects. To combat resistant infections, physicians may increase dosing of antibiotics, or resort to less safe agents, pushing the safety envelope. Thus, healthcare providers and regulatory agencies increasingly face a difficult choice of balancing the risk of infection against unacceptably high adverse event rates from an effective but relatively toxic antibiotic. For example, in July 2016, FDA imposed a new labeling warning on the toxicity of fluoroquinolones, further restricting the use of this essential class, exemplified by anti-pseudomonal agent ciprofloxacin. Anti-MRSA agent linezolid (Zyvox®) is often used beyond its approved 14-day therapy, resulting in several myelosuppression-associated adverse effects listed in the black box warning for this important drug. MicuRx is addressing the critical need for effective but safer therapeutics by designing novel new compounds with reduced toxicity and adverse events while maintaining excellent clinical efficacy.

Verinata Health

Verinata Health is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.